Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-06-16 6:10 pm Purchase | 2025-06-09 | 13D | Arvinas, Inc. ARVN | Logos Global Management LP | 4,800,000 6.400% | 4,800,000 (New Position) | Filing History |
| 2025-06-04 5:18 pm Purchase | 2025-05-29 | 13G | Prothena Corporation plc PRTA | Logos Global Management LP | 2,950,000 5.500% | 2,950,000 (New Position) | Filing History |
| 2025-05-13 7:29 pm Purchase | 2025-03-18 | 13D | Olema Pharmaceuticals, Inc. OLMA | Logos Global Management LP | 3,208,875 4.700% | 3,208,875 (New Position) | Filing History |
| 2025-04-28 7:15 pm Purchase | 2025-04-21 | 13G | Annexon, Inc. ANNX | Logos Global Management LP | 6,600,000 6.000% | 3,700,000 (+127.59%) | Filing History |
| 2025-02-14 1:40 pm Sale | 2024-12-31 | 13G | NextCure, Inc. NXTC | Logos Global Management LP | 0 0.000% | -2,500,000 (Position Closed) | Filing History |
| 2025-02-14 1:34 pm Sale | 2024-12-31 | 13G | Elevation Oncology, Inc. ELEV | Logos Global Management LP | 0 0.000% | -3,500,000 (Position Closed) | Filing History |
| 2024-11-27 2:22 pm Purchase | 2024-11-25 | 13G | GlycoMimetics, Inc. GLYC | Logos Global Management LP | 5,000,000 7.800% | 5,000,000 (New Position) | Filing History |
| 2024-11-14 7:13 pm Purchase | 2024-09-30 | 13G | Unicycive Therapeutics, Inc. UNCY | Logos Global Management LP | 5,078,927 4.900% | 5,078,927 (New Position) | Filing History |
| 2024-11-14 7:05 pm Sale | 2024-09-30 | 13G | Elevation Oncology, Inc. ELEV | Logos Global Management LP | 3,500,000 5.900% | -150,000 (-4.11%) | Filing History |
| 2024-11-14 6:59 pm Purchase | 2024-09-30 | 13G | NextCure, Inc. NXTC | Logos Global Management LP | 2,500,000 8.900% | 499,540 (+24.97%) | Filing History |
| 2024-11-14 6:55 pm Sale | 2024-09-30 | 13G | Cybin Inc. CYBN | Logos Global Management LP | 0 0.000% | -1,052,632 (Position Closed) | Filing History |
| 2024-11-14 6:51 pm Sale | 2024-09-30 | 13G | aTyr Pharma, Inc. ATYR | Logos Global Management LP | 1,750,000 2.100% | -4,050,000 (-69.83%) | Filing History |
| 2024-11-14 6:46 pm Sale | 2024-09-30 | 13G | Annexon, Inc. ANNX | Logos Global Management LP | 2,900,000 2.700% | -4,044,444 (-58.24%) | Filing History |
| 2024-11-14 6:40 pm Purchase | 2024-09-30 | 13G | Adverum Biotechnologies, Inc. ADVM | Logos Global Management LP | 416,666 2.000% | 416,666 (New Position) | Filing History |
| 2024-10-23 6:09 pm Purchase | 2024-10-16 | 13G | Bright Minds Biosciences Inc. DRUG | Logos Global Management LP | 100,000 2.200% | 100,000 (New Position) | Filing History |
| 2024-08-27 5:22 pm Purchase | 2024-03-14 | 13G | Cybin Inc. CYBN | Logos Global Management LP | 1,052,632 5.300% | 1,052,632 (New Position) | Filing History |
| 2024-08-13 6:53 pm Purchase | 2024-08-09 | 13D | Design Therapeutics, Inc. DSGN | Logos Global Management LP | 4,232,627 7.500% | 1,420,126 (+50.49%) | Filing History |
| 2024-06-06 6:49 pm Sale | 2024-06-04 | 13D | Olema Pharmaceuticals, Inc. OLMA | Logos Global Management LP | 3,248,818 5.800% | -1,018,130 (-23.86%) | Filing History |
| 2024-04-01 6:34 pm Purchase | 2024-04-01 | 13G | NextCure, Inc. NXTC | Logos Global Management LP | 2,000,460 7.200% | 2,000,460 (New Position) | Filing History |
| 2024-02-22 3:47 pm Purchase | 2024-02-06 | 13G | Adverum Biotechnologies, Inc. ADVM | Logos Global Management LP | 1,500,000 7.200% | 1,500,000 (New Position) | Filing History |